HOME >> BIOLOGY >> NEWS
New transgenic rat model of ALS expands research possibilities

A team of scientists led by drug maker Wyeth-Ayerst and Johns Hopkins have engineered and tested a new rat model of Lou Gehrig's disease they say is far easier to work with than earlier mouse models.

Because of their larger size, the rats should expedite evaluation of novel treatments, such as those using stem cells, as well as deepen understanding of the fatal disease also known as amyotrophic lateral sclerosis (ALS), the scientists say. The "transgenic" rat, which carries a human gene, already has revealed the important role played by brain cells called astrocytes, a role obscured in mice.

The ALS rat, believed to be the first transgenic rat model of a neurodegenerative disease, moves from onset of symptoms through to ALS-like disability more quickly than ALS mice, making changes in cells in the rats more striking from day to day, the scientists report in the Jan. 29 online edition of the Proceedings of the National Academy of Sciences.

"The transgenic rats are a powerful tool," says neurologist Jeffrey Rothstein, M.D., director of the Center for ALS Research at Johns Hopkins and an author of the report. "Mice are just too small, for example, for reliable infusions into their spinal cords, the direction research on stem cell treatment is heading."

Scientists at Wyeth-Ayerst engineered the rats to carry an abnormal human gene for superoxide dismutase (SOD1), an enzyme that normally breaks down free radicals, highly reactive molecules that quickly damage DNA and kill cells. Faulty SOD1 behavior, caused by a number of different genetic mutations, is at the root of roughly one-fifth of inherited ALS cases.

The SOD1 rats, like the SOD1 mice before them, develop a disease very similar to ALS in humans, which is characterized by the death of motor nerve cells throughout the central nervous system. The rats are "symptom-free" for a longer time, but then deteriorate much more rapidly than the mice.

While the faster disease
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
28-Jan-2002


Page: 1 2 3

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. UGA researchers use transgenic trees to help clean up toxic waste site
3. Could Bt transgenic crops have nutritionally favourable effects on insects?
4. Scientists transgenic chicken aids embryo research
5. Scientists report first transgenic animal developed via retroviral DNA insertion into male germ-line stem cells
6. Eating transgenic sausages
7. Dairy scientist advances field of transgenics and knowledge of growth hormones
8. Scientists develop most efficient mouse cloning strategy to date, create transgenic clone
9. New transgenic mouse likely to advance Alzheimers disease research
10. University of Florida researchers test drug from transgenic sheep in study at Shands at UF teaching hospital
11. Jefferson scientists create first transgenic mouse model of hepatitis B-based liver disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch ... held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO ... Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy of Cancer (SITC) strongly ... Administration’s recently published fiscal year 2018 budget request. , This proposal ... $5.8 billion or roughly 20% of its total budget. If applied proportionally across NIH, ...
(Date:3/22/2017)... -- Personal Genome Diagnostics Inc. (PGDx) today announced an ... U.S. Department of Veterans Affairs (VA) that replaces ... new CancerSELECT ™ 125 test. CancerSELECT 125 ... that includes microsatellite instability status (MSI), a biomarker ... inhibitor immunotherapies. CancerSELECT 125 will be available to ...
(Date:3/20/2017)... ... March 20, 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany ... ! Sponsored by the Parenteral Drug Association (PDA), the New York Interphex Show ... professionals in attendance and more than 625 exhibitors, the educational and networking opportunities are ...
Breaking Biology Technology:
Cached News: